安进狄诺塞麦适应症

Clinical treatment methods for bone metastases are limited, and systemic treatment is difficult to control. Moreover, most of them are osteolytic bone metastases, and bone destruction is difficult to reconstruct. The most important treatment is regular intravenous administration of bisphosphonates once a month. There is a subcutaneous injection drug that has better anti-bone metastasis effect than traditional bisphosphonates, which has been approved by the FDA and has been included in the NCCN guidelines.

RANKL is a transmembrane or soluble protein that plays an important role in the formation, function, and survival of osteoclasts and cells responsible for bone resorption, regulating the release of calcium from bone. Through RANKL stimulation, osteoclast activity is enhanced, mediating the occurrence of bone metastasis bone pathology in solid tumors. Denosumab can bind to the RANKL protein, preventing RANKL from binding to the receptor RANK expressed on the surface of osteoclasts, precursor cells, and osteoclast-like giant cells to activate subsequent malignant processes, thus exerting an anti-bone metastasis effect. 

Amgen focuses on disease areas with huge medical needs that are far from being met, and uses its advanced experience in biopharmaceuticals to make outstanding contributions to improving human health and quality of life. Since its founding in 1980, Amgen has become one of the world's leading independent biotechnology companies, providing innovative drugs to millions of patients in more than 100 countries and regions around the world, and also has a number of promising drugs in development.

Amgen was approved for three indications: (1) Prevention of bone-related events in bone metastases from solid tumors, excluding patients with multiple myeloma. Instructions for use: 120mg, once every 4 weeks. Also infuse calcium or vitamin D to prevent hypocalcemia. (2) Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications. Instructions for use: 120 mg, once every 4 weeks. In the first month of treatment, add 120 mg on the 8th and 15th days respectively. (3) Hypercalcemia in bisphosphonate-resistant malignant tumors. The usage method is the same as the second indication.

Recommended related hot articles: /newsDetail/93098.html